Fabrication of Miniaturized Paper-Based Microfluidic Devices (MicroPADs)
Fabrication of Miniaturized Paper-Based Microfluidic Devices (MicroPADs)
复制标题
DOI：
10.1038/s41598-018-37029-0
复制
发表时间：
2019-01-09
影响因子：
4.6
通讯作者：
Martinez, Nathaniel W.
中科院分区：
文献类型：
--
作者：
Strong, E. Brandon;Schultz, Spencer A.;Martinez, Nathaniel W.
微流控纸基分析设备(MicroPADs)正在成为具有成本效益的便携平台，用于医疗现场分析。MicroPAD制造的一个根本限制是大多数用于构图纸的方法的不精确性质。目前的工作表明，通过蜡印形成的纸张可以通过高碘酸盐处理来实现微型化，以生产更高分辨率、高保真的微型PADs。通过在不同浓度的高碘酸钠(NaLO(4))中浸泡不同时间来确定最佳的微型化参数。根据高碘酸盐的浓度和反应时间的长短，这种处理使微型PADs的表面积减少了高达80%。通过在0.5-M NaLO(4)中浸泡48小时，器件的表面积缩小了78%，这种处理允许制造宽度为301微米的功能通道和宽度为387微米的疏水屏障。小型化的器件与氧化还原比色法和酶反应兼容。这种小型化技术为在纸基流体设备中制造亚毫米尺寸的特征提供了一种新的选择，而不需要专门的设备，并可以实现微型PAD的新功能和应用。
Microfluidic paper-based analytical devices (microPADs) are emerging as cost-effective and portable platforms for point-of-care assays. A fundamental limitation of microPAD fabrication is the imprecise nature of most methods for patterning paper. The present work demonstrates that paper patterned via wax printing can be miniaturized by treating it with periodate to produce higher-resolution, high-fidelity microPADs. The optimal miniaturization parameters were determined by immersing microPADs in various concentrations of aqueous sodium periodate (NalO(4)) for varying lengths of time. This treatment miniaturized microPADs by up to 80% in surface area, depending on the concentration of periodate and length of the reaction time. By immersing microPADs in 0.5-M NalO(4) for 48 hours, devices were miniaturized by 78% in surface area, and this treatment allowed for the fabrication of functional channels with widths as small as 301 mu m and hydrophobic barriers with widths as small as 387 mu m. The miniaturized devices were shown to be compatible with redox-based colorimetric assays and enzymatic reactions. This miniaturization technique provides a new option for fabricating sub-millimeter-sized features in paper-based fluidic devices without requiring specialized equipment and could enable new capabilities and applications for microPADs.